The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cure candidates: Characteristics of >10yr progression-free survivors (PFS-10) and continuous CR (CCR-10) after total therapy 1 and 2 (TT1, TT2) for multiple myeloma (MM).
Sarah Waheed
No relevant relationships to disclose
Frits Van Rhee
No relevant relationships to disclose
Adam Rosenthal
No relevant relationships to disclose
Saad Zafar Usmani
Consultant or Advisory Role - Celgene
Research Funding - Celgene; Millennium; Onyx
Mian Adnan Waheed
No relevant relationships to disclose
Antje Hoering
No relevant relationships to disclose
Bart Barlogie
Consultant or Advisory Role - Celgene; Millennium
Research Funding - Celgene; Millennium